{"id":"dbi-002-gel","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Skin irritation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"DBI-002 Gel works by altering the balance of the skin microbiome, reducing inflammation and improving the integrity of the skin barrier. This is achieved through the application of a specific formulation that selectively targets and modifies the skin microbiome, leading to improved symptoms of atopic dermatitis.","oneSentence":"DBI-002 Gel is a topical treatment that modulates the skin microbiome to improve symptoms of atopic dermatitis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:31:30.632Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT04937920","phase":"PHASE2","title":"A Trial to Evaluate the Safety and Antimicrobial Efficacy of DBI-002 Probiotic in Adults With Tinea Versicolor","status":"COMPLETED","sponsor":"DermBiont, Inc.","startDate":"2021-03-16","conditions":"Tinea Versicolor","enrollment":34},{"nctId":"NCT05491603","phase":"PHASE2","title":"A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis","status":"SUSPENDED","sponsor":"DermBiont, Inc.","startDate":"2023-11","conditions":"Onychomycosis","enrollment":60},{"nctId":"NCT05493488","phase":"PHASE2","title":"A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis","status":"UNKNOWN","sponsor":"DermBiont, Inc.","startDate":"2022-09-08","conditions":"Tinea Pedis","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":334928,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"DBI-002 Gel","genericName":"DBI-002 Gel","companyName":"DermBiont, Inc.","companyId":"dermbiont-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"DBI-002 Gel is a topical treatment that modulates the skin microbiome to improve symptoms of atopic dermatitis. Used for Moderate to severe atopic dermatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}